Csiszar Anna, Pacher Pal, Kaley Gabor, Ungvari Zoltan
Department of Physiology, New York Medical College, Valhalla, 10595, USA.
Curr Vasc Pharmacol. 2005 Jul;3(3):285-91. doi: 10.2174/1570161054368616.
Epidemiological studies demonstrated that even in the absence of other risk factors (e.g. diabetes, hypertension, hypercholesterolemia), advanced age itself significantly increases cardiovascular morbidity. Although aging is inevitable, cardiovascular gerontologists recognize that a better understanding of the aging process in the not-so-distant future will lead to pharmacological interventions that considerably delay the functional decline of the cardiovascular system. Since the original publishing of the free radical theory of aging, an increased production of reactive oxygen species has been implicated both in the aging process and the development of age-related cardiovascular diseases. This review focuses on the role of oxidative and nitrosative stress in cardiovascular dysfunction in aging, downstream mechanisms including activation of NF- kappaB, and the role of poly(ADP-ribose)polymerase (PARP) and longevity genes that are linked to regulation of cellular redox status and oxidative stress resistance (p66(shc), sirtuins, FOXO transcription factors).
流行病学研究表明,即使不存在其他风险因素(如糖尿病、高血压、高胆固醇血症),高龄本身也会显著增加心血管疾病的发病率。尽管衰老不可避免,但心血管老年病学家认识到,在不久的将来更好地理解衰老过程将带来药物干预措施,从而大大延缓心血管系统的功能衰退。自从衰老的自由基理论首次发表以来,活性氧的产生增加被认为与衰老过程以及与年龄相关的心血管疾病的发生都有关联。本综述重点关注氧化应激和亚硝化应激在衰老过程中心血管功能障碍中的作用、包括核因子κB激活在内的下游机制,以及聚(ADP-核糖)聚合酶(PARP)和长寿基因的作用,这些基因与细胞氧化还原状态调节和氧化应激抗性(p66(shc)、沉默调节蛋白、FOXO转录因子)相关。